These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17803331)

  • 1. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations.
    Prosser LA; Hammitt JK; Keren R
    Pharmacoeconomics; 2007; 25(9):713-26. PubMed ID: 17803331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?
    Ungar WJ
    Pharmacoeconomics; 2011 Aug; 29(8):641-52. PubMed ID: 21604821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring health-related quality of life for child maltreatment: a systematic literature review.
    Prosser LA; Corso PS
    Health Qual Life Outcomes; 2007 Jul; 5():42. PubMed ID: 17634122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses.
    Rankin J; Rowen D; Howe A; Cleland JGF; Whitty JA
    Heart Fail Rev; 2019 Jul; 24(4):549-563. PubMed ID: 30903357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US.
    Ladapo JA; Neumann PJ; Keren R; Prosser LA
    Pharmacoeconomics; 2007; 25(10):817-28. PubMed ID: 17887804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing the health states associated with Chlamydia trachomatis infections and their sequelae: a systematic review of economic evaluations and primary studies.
    Jackson LJ; Auguste P; Low N; Roberts TE
    Value Health; 2014; 17(1):116-30. PubMed ID: 24438725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?
    Rowen D; Rivero-Arias O; Devlin N; Ratcliffe J
    Pharmacoeconomics; 2020 Apr; 38(4):325-340. PubMed ID: 31903522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preference Elicitation Techniques Used in Valuing Children's Health-Related Quality-of-Life: A Systematic Review.
    Bailey C; Howell M; Raghunandan R; Salisbury A; Chen G; Coast J; Craig JC; Devlin NJ; Huynh E; Lancsar E; Mulhern BJ; Norman R; Petrou S; Ratcliffe J; Street DJ; Howard K; Viney R;
    Pharmacoeconomics; 2022 Jul; 40(7):663-698. PubMed ID: 35619044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing the Clinical Effectiveness of Therapeutics.
    Listl S; Faggion CM
    J Evid Based Dent Pract; 2016 Jun; 16(2):86-9. PubMed ID: 27449834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Income effects of reduced health and health effects of reduced income: implications for health-state valuation.
    Sculpher MJ; O'Brien BJ
    Med Decis Making; 2000; 20(2):207-15. PubMed ID: 10772358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the societal approach wide enough to include relatives? Incorporating relatives' costs and effects in a cost-effectiveness analysis.
    Davidson T; Levin LA
    Appl Health Econ Health Policy; 2010; 8(1):25-35. PubMed ID: 20038191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.
    Lamsal R; Yeh EA; Pullenayegum E; Ungar WJ
    Pharmacoeconomics; 2024 Feb; 42(2):199-217. PubMed ID: 37945777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory.
    Lipman SA; Brouwer WBF; Attema AE
    Value Health; 2019 Jul; 22(7):816-821. PubMed ID: 31277829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating quality of life changes into economic evaluations of health care: an overview.
    Blumenschein K; Johannesson M
    Health Policy; 1996 May; 36(2):155-66. PubMed ID: 10158766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism?
    Birch S; Donaldson C
    Soc Sci Med; 2003 Mar; 56(5):1121-33. PubMed ID: 12593883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological issues raised by preference-based approaches to measuring the health status of children.
    Petrou S
    Health Econ; 2003 Aug; 12(8):697-702. PubMed ID: 12898666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time.
    Grosse SD; Pike J; Soelaeman R; Tilford JM
    Pharmacoeconomics; 2019 Apr; 37(4):461-473. PubMed ID: 30953263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.